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A pandemic of COVID-19 made an appearance in Wuhan, China, in late De-
cember 2019 and rapidly became a serious concern worldwide, with killing more than 
238000 people until 3rd May 2020. Given the fact that a vaccine against the virus 
probably won’t be available anytime in the near future, the therapeutic strategies have 
become more prominent. Many supposedly effective drugs are under evaluation which 
may hinder the replication of SARS-CoV-2, and subsequently the infection. Lately on 
1th may 2020, FDA authorized the use of experimental drug, Remdesivir for “emer-
gency purpose” in COVID-19 cases. Chloroquine and hydroxychloroquine, among the 
very first under-trial drugs, have been revealed to have promising impacts in treatment 
of SARS-CoV2. Broad-spectrum antivirals as well as HIV protease-inhibitors are still 
subject to assessment. Particularly angiotensin-converting enzyme 2 (ACE2) inhibitors 
are increasingly taken into consideration because of ACE2 being recognized as a host-
cell receptor for COVID-19. Immune-Enhancement therapy by Interferons and Intrave-
nous immunoglobulin (IVIG) has been shown to be effective in some cases. Moreover, 
Convalescent Plasma Therapy and auxiliary blood purification were considered as the 
treatment of SARS-CoV2 infection. Among the critically ill patients, Oxygen-therapy, 
timely usage of inflammatory inhibitors, and controlling viral shedding by antivirals may 
reduce the mortality and morbidity of COVID-19.
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On December 31st, 2019, the existence of a large group of pa-
tients with a mysterious pneumonia of viral cause was brought 
to light in Wuhan, Hubei Province of China. The Chinese au-
thorities notified the world that a virus was spreading inside their 
communities. Then, on February 11th, 2020, the international 
officials, called this new coronavirus family member which 
was responsible for the disease, the “Severe Acute Respiratory 
Syndrome Coronavirus 2” (SARS-CoV-2). World Health Orga-
nization (WHO) identified the related illness as “Coronavirus 
Disease 2019” (COVID-19) [1]. Subsequently, on March 11th, 
2020, WHO decided to declare the current global dilemma, as 
a pandemic [2]. Based on the report of WHO on May 3rd, 2020, 
a total of more than 3.3 million patients globally have defi-
nite diagnosis of COVID-19, and the world death toll from the 
disease has currently surpassed 238000 which has resulted in 
a mortality rate of approximate 7.1 percent [3]. Figure 1 indi-
cates the most current distribution of COVID-19 cases in the 
world. As it’s been announced and also, as it is shown in Chart 
1, the situation in certain regions of the world is quite similar 
to an almost crisis. Europe has been tremendously affected by 
the virus in terms of both mortality and morbidity. Spain, It-
aly, along with United Kingdom are the three main countries 
having the greatest amounts of cases and deaths in European 
pacific region. In western pacific region, China accompanying 
with Singapore are considered as the two territories having the 
most significant amount of cases and deaths. Among middle 
east region countries, Iran has the greatest number of confirmed 
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never been more obvious that one of the most effective mea-
sures in these circumstances is developing an up-to-date thera-
peutic strategy and treatment plan. By conducting this narrative 
review, we’ve aimed to evaluate different medications, along 
with their drawbacks and benefits, as well as the proper critical 
care for seriously ill patients. 
DIFFERENT GROUPS OF MEDICATION 
1. Anti-Viral Drugs 
1.1 Lopinavir/Ritonavir (Kaletra): Lopinavir, classified in 
the drug group of protease inhibitors, is utilized for the treat-
ment of patients affected prolongedly with HIV-1 [8]. its mech-
anism of action  is blocking the main protease of SARS-CoV-1, 
resulting in inhibition of viral replication [9]. Real-world infor-
mation supporting the treatment of COVID-19 with Lopina-
vir/Ritonavir keeps coming out.  Chu et al. have discovered 
that Lopinavir/Ritonavir has an anti-SARS-CoV effect with-
in both in-vitro settings and clinical studies [10]. Published 
evaluations from Korea and China show reduced viral load, 
and clinical improvement of COVID-19 patients after onset 
of Lopinavir/Ritonavir treatment [11-13]. However, Cao and 
colleagues illustrated the results of comparing twice a day use 
of Lopinavir/Ritonavir 400/100 mg to standard care, for treat-
ing the pneumonia caused by SARS-CoV-2. This study up-
shot, demonstrated no benefit regarding a Lopinavir/Ritonavir 
treatment beyond standard card [14]. Considering the currently 
available data, it is yet to be determined whether Lopinavir/
Ritonavir could significantly affect the status of COVID-19 pa-
tients, either as monotherapy or in combination-therapy. More-
over, close monitoring is needed during the administration of 
this drug, because particularly elevated levels of AST or ALT 
suggesting the gastrointestinal complications and hepatoxicity 
may exclude patients with COVID-19 from clinical trials [15].
1.2 Darunavir: Darunavir is a 2nd generation drug in HIV-
1 protease inhibitor family. On February 4th, 2020, research-
ers in China declared that Darunavir can desirably control the 
SARS-CoV-2 in laboratory-based setup [16]. Cell-based exper-
imental studies established that Darunavir within in-vitro situ-
ation remarkably hindered replication of virus, when having 
300 ?M concentration. It was also determined that its inhibition 
efficiency was 280-fold compared to what was observed in the 
untreated group [16]. The combination of Darunavir and Ri-
tonavir has poor in-vitro efficacy against SARS-CoV-2. Taking 
into consideration the similar mechanism od actions of Lopina-
vir and Darunavir, it is improbable that Darunavir would render 
any benefit if Lopinavir does not [17]. 
1.3 Favipiravir: Favipiravir, a novel example of RNA-depen-
dent type RNA polymerase inhibitor, can selectively impede 
the RNA polymerase in a wide diversity of viruses, including 
influenza virus, to an extent that even influenza viral particles, 
which are refractory to other antiviral agents can be effica-
ciously contained by Favipiravir. As well as its anti-influenza 
activity, Favipiravir can actually block the replication of a wide 
diversity of viral particles including RNA viruses [18]. Favip-
iravir is firstly transformed into an active phosphoribosyl struc-
ture within cells, then RNA polymerase of virus identifies it as 
cases and fatality rate [3]. Clinically, fever, dry cough, dyspnea 
and fatigue are the most common manifestations of the dis-
ease, while the manifestations related to the upper airways are 
not noticeable. Gastrointestinal manifestations also have been 
seen in some cases. Septic shock is among the main concerning 
complications in COVID-19 patients, as well as acute respira-
tory distress syndrome (ARDS) [4]. Various types of radiologic 
findings commonly show multiple ground glass and infiltrative 
views in pulmonary tissue on both sides. Chest CT scan is uti-
lized for the diagnosis of the disease as a salient addition to the 
RT-PCR test [5]. The treatment modalities are still remained as 
the big missing piece of the novel coronavirus puzzle. While 
the effectiveness of different variety of drugs are still under 
evaluation, optimized supportive care is the centerpiece of 
treatment. according to the efficacy which was shown on other 
family members of SARS-CoV2 like Middle East Respiratory 
Syndrome (MERS) and Severe Acute Respiratory Syndrome 
Coronavirus 1 (SARS-CoV-1), some drugs have been under in-
vestigation [6]. Moreover, as the hyper-inflammatory state and 
cytokine storming is considered as the concerning complica-
tion of COVID-19, particular interests in the field of evaluating 
cytokine release inhibitors have been increased [7]. All that has 
been briefly stated, indeed is pointing to this fact that how great 
of a crisis COVID-19 situation is, and how much more trouble-
some it could get, if proper measures will not be taken. It has 
Chart 1: Comparison of confirmed cases and deaths of COVID-19 
outbreak in 6 regions of the world in the May 3rd, 2020
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a substrate, which in turn hampers RNA polymerase activity 
effectively [19]. Ergo, Favipiravir might provide potential anti-
viral features against SARS-CoV-2, being a RNA virus itself. A 
study about Favipiravir was conducted which aimed at treating 
COVID-19. This trial depicted that Favipiravir showed more 
influential antiviral activity compared to Lopinavir/Ritonavir 
[20]. Although, it is crucial to understand that this agent is still 
being evaluated by some clinical studies, and therefore far it 
has been proven appropriately helpful against SARS-CoV-2. 
1.4 Remdesivir: Remdesivir is known as a nucleoside ana-
logue as well as a wide-spectrum antiviral agent with particular 
protective properties against Ebola virus in humans and other 
coronaviruses in non-human primates. Remdesivir selectively 
affect viral polymerases, so it is quite anticipated to have a low 
tendency to cause toxicity in humans [21]. The therapeutic val-
ue of Remdesivir was first explained in an animal experiment 
against Ebola [22]. In the mentioned study, infected rhesus 
monkeys that underwent Remdesivir treatment with once-a-
day dosing showed promising signs of suppression of viral rep-
lication in addition to protection from the fatal disease. Other 
animal experimental models underlined that Remdesivir could 
efficaciously decrease the amount of viral particles in the pul-
monary cells of the mice afflicted with MERSCoV, diminish-
ing pathological damage to the tissue, which can prevent lung 
hemorrhage [23]. In the suggested approach to the outbreak of 
COVID-19, Wang and others disclosed that Remdesivir force-
fully stops SARS-CoV-2 in low micromolar amounts, while be-
ing highly selective [24]. In the United States, Holshue and col-
leagues disclosed the first spectacularly treated patient, whose 
life had been saved by using Remdesivir [25]. Some studies 
have come up with this idea that the significance of early initi-
ation of therapy to reduce virus replication and improve tissue 
repairing is undeniable; and that is mainly because Remdesivir 
is less clinically beneficial with high-titer virus inoculum. Im-
pressively, the authors also heeded that prophylactic use of Rem-
desivir decreased MERS-CoV replication, which was quite sim-
ilar to what was found in a murine model with SARS-CoV-1 [23, 
26], and also in an in-vitro setting with SARS-CoV-2 and other 
coronaviruses [24, 26]. In March 2020, the company of Gilead 
sciences initiated randomized, open-label, multicenter Phase 3 
clinical research to assess how efficacious and safe Remdesivir 
is in 1000 adults with COVID-19 diagnosis.  On May 1st ,2020, 
Food and Drug Administration (FDA) allowed the emergency 
use of Remdesivir for critically ill COVID-19 patients [27]. 
1.5 Chloroquine and Hydroxychloroquine: Chloroquine 
has been a broadly-utilized anti-malaria agent ,which has been 
proved to be a powerful wide-spectrum antiviral in 2006 [28]. 
Moreover, Chloroquine has the characteristics of anti-inflam-
matory and immuno-modulatory by inhibiting the production of 
Tumor necrosis factor ? (TNF-?) along with Interleukin type 6 
(IL-6) [29]. In the first half of February, Wang et al. illustrated 
puissant inhibition of SARS-CoV-2 by Chloroquine when taking 
two 500-mg tablets PO  daily [24] similar to some clinical studies 
in China through this outbreak [30]. According to the works of 
Per Gao et al.,  it was indicated that chloroquine phosphate actu-
ally outdoes the control treatment in inhibiting the exacerbation 
of pneumonia, improving lungs radiographic findings, and cur-
tailing the course of the disease [30]. X. Yao et al. evaluated the 
possible doses of Chloroquine and Hydroxychloroquine to find 
the optimized dose in treatment of COVID-19. They revealed 
that within in-vitro settings Hydroxychloroquine is more potent 
than chloroquine. As a conclusion, they suggested a 800 mg dai-
ly dose of hydroxychloroquine, followed by an overall main-
tenance dose of 400 mg per day divided in two separate doses, 
which was three-fold more potent compared to the 500 mg twice 
daily administration of chloroquine in 5 days [31]. Currently the 
Figure 1. Distribution of COVID-19 patients throughout the world in May 3rd 2020.(source: World Healt Organization fact sheet 104)
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cifically when influenza has been excluded from the diagnosis.
1.9 Nitazoxanide: Nitazoxanide has demonstrated positive 
efficacy against different varieties of viruses such as influenza, 
parainfluenza, and SARS-COV-1 in some of in-vitro trials [38]. 
It is suggested that the main antiviral property of Nitazoxanide 
is concerned with inhibiting the host-regulated cycles which 
are related to replication rather than the viral pathways them-
selves [38]. Even though the in-vitro activity of Nitazoxanide 
had hopeful results as a treatment of SARS-CoV-2, in recent 
clinical trial studies [24, 38], it did not show an effective role 
in decreasing the hospitalization period or improving clinical 
manifestations in COVID-19 patients [39]. Notwithstanding, 
more clinical evaluations are required, so we could start a prop-
er discussion surrounding the effectiveness of Nitazoxanide 
against SARS-CoV-2.
2. Immune-Enhancing Drugs
2.1 Interferons: It has been depicted in various clinical stud-
ies that Interferon-? had been helpful in treatment of individ-
uals who were affected by SARS-CoV-1 [40]. In a study, it 
was delineated that Interferons can be an efficacious inhibiting 
factor of the replication in different virus genomes, for instance 
MERS virus, which in fact is considered a member of Coro-
navirus family [41]. Those findings in addition to interferon’s 
innate anti-viral ability, propounded that it can be utilized in 
the therapeutic procedure of COVID-19. Generally, both in-
terferon-? and interferon-? have been proven to suppress the 
viral replication of SARS-CoV in-vitro [42]. But on a more 
specific note, research conducted within laboratory-based set-
tings firmly indicated that interferon-? in concentrations great-
er than1000 U/ml, could slightly hinder SARS-CoV replication 
[43]. In a retrospective study conducted on patients afflicted 
with MERS who had undergone combination therapy within 
1-3 days of ICU admission, the mixture of drugs was not con-
nected with improved mortality or increased viral clearance 
[44]. Of note, it is critical to know that its downsides include 
severe cytopenia, hepatoxicity, and risk of developing fatal or 
life-threatening ischemia or infection, specifically when com-
bined with Ribavirin.
2.2 Intravenous immunoglobulin (IVIG) and Thymosin 
alpha-1: Intravenous immunoglobulin is deemed as the most 
harmless immune regulator in abiding use for every age group. 
It might also be of help in inhibiting the release of pro-inflam-
matory factors, and in turn enhance the making of anti-inflam-
matory factors [45]. as a further matter, Thymosin alpha-1 can 
increase immunity in fighting against SARS, ably containing 
the distribution of virus [46]. Accordingly, IVIG therapy and 
Thymosin alpha-1 has been considered as treatments for SARS-
CoV-2. Although, the supporting information on the matter are 
considerably poor and clinical studies are still in process.
3. Anti-Inflammatory Agents
3.1 Tocilizumab (Actemra): IL-6 is one of the key factors re-
sponsible for immunologic response and symptoms in patients 
presenting with cytokine storming syndrome [47]. Hyper-in-
flammatory responses due to elevated IL-6, has been observed 
in severe cases of COVID-19 and were related with risen mor-
tality [48]. Tocilizumab, a humanized antibody inhibiting IL-6 
evidence is quite inconclusive about the effectiveness or com-
parative effectiveness of either Hydroxychloroquine or Chloro-
quine. Moreover, Chloroquine has recently become scarce and 
even unavailable for ordering due to a huge demand for it, all 
because of a significant interest gained as a potential medicinal 
alternative for the management of COVID-19. 
1.6 Umifenovir (Arbidol): Umifenovir is a component de-
rived from indole, which has showed positive efficacy in in-
hibition of virus-to-host cell attachment in different groups of 
influenza, and type C hepatitis virus [32]. Study of Khamitov et 
al. in 2008 also corroborated the anti-viral effect of Arbidol on 
SARS-CoV in the cell cultures [33]. The works of L. Deng and 
other colleagues revealed that COVID-19 patients under the 
treatment of Arbidol combined with Lopinavir/Ritonavir had 
a significant clinical improvement in comparison with patients 
administrated with Lopinavir/Ritonavir alone [34]. A random-
ized clinical trial has illustrated that COVID-19 infected cases 
who were treated by Arbidol, had an impressive reduction in 
fatality rate along with a better efficacy of treatment, in com-
parison with those administrated with Kaletra [35]. Neverthe-
less, it is still needed to do further research on the effectivity of 
Arbidol specifically in much larger populations, so there can be 
a more solid conclusion ensured.
1.7 Ribavirin: Ribavirin is known to be a nucleoside ana-
logue with a wide variety of antiviral features. Different com-
binations of Ribavirin, Interferon, with other antiviral agents 
are currently being studied in multiple clinical trials.  Wang 
et al. assessed how efficacious in-vitro Ribavirin was versus 
SARS-CoV-2, which in fact appeared to be over 100-fold less 
effective than Remdesivir [24]. Furthermore, in a comparison 
research, the fatality rate and complications caused by ARDS 
was notably decreased within SARS-CoV-1 infected individu-
als, when undergoing the combination-therapy of both Ribavi-
rin and Ritonavir [10]. The possibility of hematologic toxicity 
at high dosages probably exceed potential clinical benefit, and 
for that reason, Ribavirin was not viewed as a feasible candi-
date for further evaluation by the WHO research and devel-
opment plan for SARS-CoV-2. A lack of in-vitro efficacy and 
toxicity profile along with poor outcomes are in fact among the 
main reasons for such matter.
1.8 Oseltamivir: Provided its antiviral powers against influ-
enza, substantial attention has been attracted to Oseltamivir, as 
a strong treatment option for COVID-19. This got more intense 
because of the preliminary report from Huang and colleagues 
in Wuhan where managed COVID-19 patients received Osel-
tamivir as well as wide-spectrum antimicrobials [36]. The only 
data evaluating Oseltamivir activity against Coronaviruses 
pointed it out to be ineffective in SARS-CoV-1 inhibition at a 
concentration of 10,000 ?M/L [37]. That is because Coronavi-
ruses do not deploy neuraminidase in the first place, so there 
is no enzyme to be blocked from use by Oseltamivir. This fact 
would also hold true for Zanamivir, Peramivir, or any other 
neuraminidase inhibitor drugs. Consequently, considering the 
crucial need for these medications in the management of in-
fluenza and rising concern for drug scarcity with Oseltamivir, 
these drugs should be avoided in patients with COVID-19 spe-
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receptors, has been the first FDA-approved therapeutic agent 
for treating different types of arthritis including rheumatoid ar-
thritis [49]. Immunotherapy with Tocilizumab is mentioned as 
a therapeutic option for severe or critical cases of COVID-19 
with increased levels of IL-6 in some of the major COVID-19 
guidelines published in different countries [50]. The optimal 
timing of administrating Tocilizumab during the disease course 
is yet to be described. Besides, a known IL-6 threshold has 
still not been introduced for progression to severe disease. It 
is essential to continue to follow the long-term results in these 
patients for fully evaluating the risk versus benefit of Tocili-
zumab, mainly because Tocilizumab might render a patient 
more prone to bacterial infection, and has been connected with 
neutropenia and thrombocytopenia [51]. 
3.2 Corticosteroids: There has been a huge amount of inter-
est and controversy surrounding the impact of corticosteroids 
in subduing critical pneumonia caused by coronaviruses. The 
potential advantage of these drugs to dull the inflammatory 
cascade observed in severe disease is required to be carefully 
assessed, while considering the apprehensions for secondary 
infections, adverse reactions, and other complications of corti-
costeroid treatment. Several examinations demonstrated no in-
fluence on results [52], one report showed diminished mortality 
in critically ill patients [53], and others have proved worse re-
sults for patients receiving steroids, including enhanced time of 
viral clearance [54], or a rise in the composite endpoint of ICU 
admission or death [55]. Some proofs regarding SARS-CoV-2 
underlined a lessened fatality in individuals with ARDS [56]. 
Because glucocorticoid could subdue immunity and could de-
tain clearance of SARS-CoV-2 [57], physicians need to me-
ticulously analyze the risks and benefits of corticosteroids on 
an individual basis. This need for pros and cons evaluation in 
individual patients and attentive contemplation of dose, is fully 
explained in COVID-19 guidelines published by China’s of-
ficials. In fact, within this very document the authors stated 
“Based on respiratory distress and chest imaging, may consider 
glucocorticoid that is equivalent to methylprednisolone one to 
two mg per kg per day for three to five days or less [58].”
4. Miscellaneous Therapeutic Measures 
4.1 Convalescent Plasma Therapy: Since no vaccine has 
been discovered for SARS-CoV-2, passive immunotherapy by 
convalescent plasma may be a helpful choice for controlling 
the infection of COVID-19 [59]. The role of convalescent 
Plasma in treatment of viral infections including influenza and 
hepatitis has been shown in clinical researches [60, 61]. Pa-
tients who are relieved from a viral infection, have high lev-
els of antibodies against the virus in their blood. The use of 
these immune factors, may prevent the excess replication and 
decrease the load of virus, as well as preventing the individual 
form being infected for another time. Since the maximum level 
of viral load happens mostly in the first seven days of the infec-
tions caused by viruses, it could be expected that convalescent 
plasma therapy in primary stages of the disease produce better 
results [59, 62]. To evaluate the efficacy of Convalescent Plas-
ma treatment, Shen C. et al. treated 5 immensely ill COVID-19 
cases who were suffering from the complication of ARDS with 
convalescent Plasma. As a result, 4 patients were relieved from 
ARDS in the second week after transfusion and the viral load 
had been noticeably reduced [63]. Notwithstanding, the small 
statistical population of the study makes it difficult to precisely 
discuss about the efficacy of convalescent Plasma in treatment 
of SARS-CoV-2 infection. 
4.2 Auxiliary Blood Purification Treatment: Angioten-
sin-converting enzyme 2 (ACE2) receptors are vastly observed 
in kidneys, which are one hundred folds greater than their dis-
tribution in the respiratory system [64, 65]. Based on the recent 
findings, ACE2 receptors are considered to be the cell entering 
receptors for the causative virus of COVID-19 [66]. Therefore, 
it could be expected that kidneys, may also be targeted by this 
virus. In SARS-CoV-2 infected patients, the excess and uncon-
trolled immune system response leads to great number of in-
flammatory factors production and release which may cause 
multi organ damage [67]. Timely initiation and persistent ther-
apy of blood purification in affected patients may improve re-
nal function. Moreover, removing the cytokines from the blood 
plasma by blood purification therapy could prevent the patient 
from cytokine storming syndrome and subsequent organ dys-
function. Furthermore, as the COVID-19 patients may have 
electrolyte disturbance induced by SARS-CoV-2 attachment to 
ACE2 receptors and associated hypokalemia [68], blood purifi-
cation could reduce the risk of water-electrolyte disorder and its 
complications. 
4.3 Angiotensin II receptor blocker (ARBs)/ Angiotensin 
converting enzyme (ACE) Inhibitors: Renin-angiotensin sys-
tem (RAS) is reported to have a crucial part in regulating acute 
viral lung injury and hypertension resulted from viral infections 
such as influenza virus and SARS-CoV [69, 70]. The pathogen-
esis of inflammatory lung disease and hypertension is associat-
ed with alterations in RAS functioning. Earmarking RAS for a 
therapy target is an efficacious clinical technique for antihyper-
tension treatment. ARBs and ACE Inhibitors, by blocking ACE/
Angiotensin II/Angiotensin 1 Receptor, have been widely used 
as medicines for cases with hypertension. New research shows 
that COVID-19 cases with hypertension have been prone to ex-
perience severe conditions [71]. Researches also indicated that 
cases with COVID-19 have elevated levels of Angiotensin II in 
comparison with healthy individuals [72]. The unusual rise in 
the levels of Angiotensin II was correlated with pulmonary in-
sufficiency and hypertension. Furthermore, it has been demon-
strated that RAS inhibitors are related to diminished mortality in 
sepsis patients [73]. Angiotensin II increases the production of 
inflammatory cytokines [74]. Inordinately elevated amounts of 
inflammatory cytokines are in fact damaging COVID-19 cases’ 
outcomes. A new research by Meng J. and others found that cas-
es undergoing therapy with ARBs or ACE Inhibitor had a lower 
serious disease prevalence and a lower peripheral blood IL-6 
level [75]. Although, no more verified clinical proof has been 
published to date.
CRITICAL CARE STRATEGIES 
Hospitalization might not be primarily required for cases with a 
mild clinical presentation, although in the second week of illness 
it is quite expected that clinical manifestations aggravate with 
the disease developing to lower respiratory tract ,which is why 
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all patients must be watched strictly [76]. Probable elements of 
danger for developing the critical form of disease can be as fol-
lows: being aged, chronic ailments such as cancer, diabetes, re-
nal disorders, liver disorders, cerebrovascular disorders, heart 
failure, and of course pulmonary disorders as well as pregnan-
cy and autoimmune conditions [48]. However, the possible risk 
factors are not just limited to what was mentioned. Whether a 
patient has to be put in the inpatient or outpatient department 
must be decided based on an individual patient-by-patient ra-
tionale. The admitted patients should stay in bed rested, being 
monitored for vital signs, and also as a strong recommenda-
tion, they should be provided with caring treatment to make 
sure that adequate intake of energy and balance for pH levels, 
electrolytes and water along with other inner environment fac-
tors are all maintained. The patient has to be watched for blood 
routine test, CRP, PCT, arterial blood gas analysis, organ func-
tion tests as well as chest imaging. The laboratory findings has 
showed to be predictable for the prognosis of COVID1-9 [77]. 
In highly ill patients, controlling the severity of the condition 
and enhancing the quality of respiratory status is based on three 
key principles:
1. Oxygen Therapy 
An efficacious oxygen therapy should be provided for the 
patient, being constituted of nasal cannula, non-invasive ven-
tilation (NIV), high flow nasal oxygen (HFNO) therapy, and 
invasive mechanical ventilation considering patient respiratory 
status [76, 78]. Oxygen therapy has always been the first option 
introduced to cases afflicted with shock, hypoxemia, respirato-
ry distress and severe respiratory infections. There are certain 
measures concerned with oxygenation that can impressively 
help patients get better [79]. 
HFNO has always been among the effective measures. HFNO 
can bestow a Fraction of inspired oxygen (FiO2) of up to 1.0, 
and 60 Liter per minute of gas flow [80]. HNFO as against stan-
dard oxygen therapy, can effectually decrease the necessity of 
tracheal intubation. There are particular contraindications such 
as patients afflicted with abnormal mental status, hypercapnia, 
multi-organ failure and hemodynamic instability must not be 
provided with HFNO [76]. However, HFNO might be harmless 
to utilize in individuals with non-aggravating hypercapnia of 
mild to moderate degree. With all that being mentioned, it’s im-
portant to note that if the respiratory distress doesn’t get better 
or even gets worse immensely while receiving HFNO (gas flow 
of more than 50 L/min, FiO2 of more than 70%, for one hour), 
the method of breathing support has to be altered [76, 80].
NIV, as the second strategy for respiratory support, renders 
a definite positive-pressure ventilation provided by the sealed 
mask. For increasing oxygenation, HFNO might be of use ac-
companying fitful short-term NIV (1 to 2 hours) [76, 81]. But 
in the event of pandemic viral diseases resulting in hypoxemic 
respiratory failure, NIV guidelines do recommend to utilize re-
spiratory support treatment. A few evidence have demonstrated 
that NIV has an increased rate of failure in MERS cases [76, 
82]. 
Invasive mechanical ventilation as the third supportive means 
for respiration, should be carried out immediately if ARDS 
keeps getting worse under the support of HFNO or NIV [83]. 
In fact, if the demand for FiO2 and gas flow is more than 70% 
and 50 L/min, respectively, endotracheal intubation is indicated 
[76]. Endotracheal intubation should be implemented by expe-
rienced professionals who have the expertise, while considering 
all airborne precautions. That’s mainly because endotracheal in-
tubation is a procedure that might create abundant amounts of 
transmissible aerosols. 
Extracorporeal Life Support (ECLS) as the final strategy for re-
spiratory support, is thought of as a strong recommendation in 
the cases that have refractory type of hypoxemia which is hard to 
be treated using protective lung ventilation [84]. Whilst the steps 
of invasive mechanical ventilation are going on, if the individ-
ual keeps staying in hypoxia condition, accompanied with risen 
carbon dioxide partial pressure, particularly after prone ventila-
tion and muscle relaxation, it is crucial to carry out ECLS [76], 
Although, it is strongly indicated that ECLS treatment should 
only be implemented in the presence of adequate expertise [84, 
85]. Presently, the ECLS in ICU offers two settings of Extra-
corporeal Membrane Oxygenation (ECMO): The VV-ECMO (in 
which the blood gets oxygenized by membrane oxygenator be-
fore returning to right atrium through internal jugular vein), and 
VA-ECMO (in which the blood gets oxygenized by membrane 
oxygenator  straight before getting into aortic system through 
femoral artery). As a matter of fact, in some severe ARDS cases 
only if the lung injury score exceeds 3 or the pH becomes less 
than 7.2, ECMO might be of use but not for all ARDS patients 
[76, 85].
2. Utilizing Antiviral Agents 
The administration of powerful antiviral agents for limiting the 
replication of virus could be of help in improving the condition 
of patient. Indeed, it is quite implausible to be released from 
intensive respiratory ventilation and to improve oxygen satura-
tion without the proper use of antivirals [86]. In recent case-con-
trol study of Q. Cai and others, cases treated by Favipiravir plus 
aerosol inhalation of Interferon-? demonstrated a considerable 
viral clearance time compared to control arm group who under-
went the combination-therapy of Lopinavir/Ritonavir and Inter-
feron-?. Additionally, chest x-ray of patients under the treatment 
of Favipiravir showed remarkable improvement in this study 
[87]. In other recent studies, Remdesivir is deemed as another 
useful drug in managing the viral load, and ameliorating patients 
admitted to intensive critical care units [86]. 
3. Inhibiting Cytokine Release 
The S component of the SARS-COV-2 attaches to the ACE2 
receptor of host-cell and releases RNA after the fusion with cell 
membrane. Pattern recognition receptor (PRRs) of host-cell 
which are mainly considered as Toll like receptors (TLR) will 
recognize the viral RNA [88]. These complicated signaling pro-
cedures will lead to production of Interferons and a series of 
inflammatory cytokines [89]. Based on the mentioned molecular 
findings, it could be expected that drug administration of inter-
ferons which are thought as the downstream cascade molecules 
of immune response to SARS-CoV-2, may enhance the immu-
nity against COVID-19. On the other hand, triggering of series 
immune response and cytokine storming may lead the patient 
into life-threatening condition, in which some pro-inflammato-
ry and inflammatory factors have been showed to increase in 
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COVID-19 patient’s plasma considering Interferon gamma, 
TNF- ?, Interleukin types of 1, 2, 4, 6, 7, and 10 [36, 90]. Time-
ly Inhibition of cytokine release expectedly could help prevent 
the threatening complications in patients. The appropriate on-
set of administrating and dosing range of anti-inflammatory 
drugs including Tocilizumab; both required to be more evaluat-
ed; are vital to be considered. Furthermore, there are plenty of 
challenges to be faced for using such drugs which could have 
negative impact in treatment of COVID-19. Some of the most 
troublesome of which includes the high expense, black market 
intervention and their unavailability [76].
CONCLUSION
Despite the fact that several months have passed from the 
onset of COVID-19 pandemic, a solid comprehensive treat-
ment strategy which is adequately reliable, has not been ful-
ly established. However, the recent studies have shown more 
promising effects of particularly Remdesivir on SARS-CoV-2 
among anti-viral drugs as well. Oxygenation is the first main-
stay of treatment in COVID-19 ill patients in which the type of 
support differs according to their condition, including HFNO, 
NIV, intubation and ECMO. Interferons, intravenous Immuno-
globulins, and Thymosin ?-1 may increase immunity in fight-
ing against COVID-19. Inhibition of inflammatory factors and 
cytokine storming could have a critical role in the progress of 
the disease. An important key is the time of initiation and dos-
age of these drugs. Treatment with convalescent plasma and 
Auxiliary Blood Purification may be life-giving in some cases.
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